BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2648721)

  • 21. [Preparation and identification of monoclonal antibodies against different epitopes on TAG-72 antigen].
    Xu M
    Zhonghua Zhong Liu Za Zhi; 1993 Nov; 15(6):431-4. PubMed ID: 7515344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications of immunocytochemistry to clinical cytology.
    Johnston WW; Szpak CA; Thor A; Simpson JF; Schlom J
    Cancer Invest; 1987; 5(6):593-611. PubMed ID: 3327572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of cancer cells in peritoneal fluid or washing by immunocytochemical staining with monoclonal antibodies].
    Zhao Y
    Zhonghua Fu Chan Ke Za Zhi; 1992 May; 27(3):159-61, 189. PubMed ID: 1382925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast carcinoma in bronchoalveolar lavage. A cytologic and immunocytochemical study.
    Radio SJ; Rennard SI; Kessinger A; Vaughan WP; Linder J
    Arch Pathol Lab Med; 1989 Apr; 113(4):333-6. PubMed ID: 2705864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immunoreactivity of normal tissues from dogs, using monoclonal antibody B72.3.
    Clemo FA; DeNicola DB; Zimmermann JL
    Am J Vet Res; 1994 Aug; 55(8):1139-47. PubMed ID: 7978655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactivity of monoclonal antibody F36/22 with human ovarian adenocarcinomas.
    Croghan GA; Wingate MB; Gamarra M; Johnson E; Chu TM; Allen H; Valenzuela L; Tsukada Y; Papsidero LD
    Cancer Res; 1984 May; 44(5):1954-62. PubMed ID: 6370421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study of the tumor cells.
    Guzman J; Hilgarth M; Bross KJ; Ross A; Wiehle U; Kresin V; Grunert F; von Kleist S
    Acta Cytol; 1988; 32(4):519-22. PubMed ID: 3041721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of cytologic examination of peritoneal washings in patients with endometrial carcinoma.
    Szpak CA; Creasman WT; Vollmer RT; Johnston WW
    Acta Cytol; 1981; 25(6):640-6. PubMed ID: 6171978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
    Wieczorek TJ; Krane JF
    Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Müllerian inclusions in peritoneal washings. Potential source of error in cytologic diagnosis.
    Sneige N; Fernandez T; Copeland LJ; Katz RL
    Acta Cytol; 1986; 30(3):271-6. PubMed ID: 3012920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC; Jhala NC; Shultz JJ; Chhieng DC
    Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of cytologic peritoneal washings.
    Willett GD
    Clin Lab Med; 1985 Jun; 5(2):265-74. PubMed ID: 3896625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The histologic subtype of ovarian tumors affects the detection rate by pelvic washings.
    Fadare O; Mariappan MR; Wang S; Hileeto D; McAlpine J; Rimm DL
    Cancer; 2004 Jun; 102(3):150-6. PubMed ID: 15211473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New monoclonal antibody, 1C5, reactive with human cervical adenocarcinoma of the uterus, with immunodiagnostic potential.
    Koizumi M; Uede T; Shijubo N; Kudo R; Hashimoto M; Kikuchi K
    Cancer Res; 1988 Nov; 48(22):6565-72. PubMed ID: 3052807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
    Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
    Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncofetal antigens as tumor markers in the cytologic diagnosis of effusions.
    Orell SR; Dowling KD
    Acta Cytol; 1983; 27(6):625-9. PubMed ID: 6196931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
    Myers RB; Schlom J; Srivastava S; Grizzle WE
    Mod Pathol; 1995 Apr; 8(3):260-5. PubMed ID: 7617651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.